Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open Label, Dose Escalation Study of NM8074 in Subjects With C3 Glomerulopathy (C3G)

NCT05647811 is registered in ClinicalTrials.gov with NovelMed Therapeutics as lead sponsor.

NCT NCT05647811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05647811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open Label, Dose Escalation Study of NM8074 in Subjects With C3 Glomerulopathy (C3G)
Lead sponsor
NovelMed Therapeutics
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
May 31, 2027
Completion date
July 31, 2030
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

c3 glomerulopathy